A Phase 2 Study of AZD6244 in Biliary Cancers.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Selumetinib (Primary)
- Indications Biliary cancer
- Focus Biomarker; Therapeutic Use
- 22 Apr 2016 Status changed from active, no longer recruiting to completed.
- 22 Apr 2016 Status changed from active, no longer recruiting to completed.
- 18 Jul 2012 Additional trial identifiers (NCT01645644, NCI2009-00251), centers identified as reported by ClinicalTrials.gov.